---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-053933"
form_type: "8-K"
ticker: "NMRA"
cik: "0001885522"
company_name: "Neumora Therapeutics, Inc."
filed_at: "2024-05-07T23:59:59+00:00"
generated_at: "2026-06-02T20:53:31.927988+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Neumora Q1 net loss $53.7M; navacaprant Phase 3 MDD data on track for Q4 2024; NMRA-266 clinical hold with FDA

## Summary
- Net loss of $53.7M in Q1 2024 vs $35.6M in Q1 2023; R&D expense $45.8M, G&A $14.3M.
- Cash, cash equivalents and marketable securities of $423.0M; expected to fund operations into 2026.
- Topline Phase 3 data from navacaprant KOASTAL-1 in MDD expected Q4 2024; Phase 2 bipolar depression trial to start Q2 2024.
- NMRA-511 Phase 1 complete; Phase 1b in Alzheimer's agitation to start Q2 2024 with data in 2025.
- FDA placed clinical hold on NMRA-266 Phase 1 study; company working to resolve; additional M4 PAM IND expected 2025.

## SEC filing metadata
- accession: 0000950170-24-053933
- form_type: 8-K
- ticker: NMRA
- cik: 0001885522
- company_name: Neumora Therapeutics, Inc.
- filed_at: 2024-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1885522/000095017024053933/0000950170-24-053933-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1885522/000095017024053933/nmra-20240507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-053933
- JSON: https://secwatch.observer/filing/0000950170-24-053933.json
- Plain text: https://secwatch.observer/filing/0000950170-24-053933.txt

## Key facts
- Earnings Releases
  Neumora Therapeutics, Inc. reported the first quarter ended March 31, 2024 results: net income net loss of $53.7 million.
  - Period: the first quarter ended March 31, 2024
  - Net income: net loss of $53.7 million
  - Result: reported results
  source text: announced its financial results for the first quarter ended March 31, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1885522/000095017024053933/0000950170-24-053933-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.